Allergan PLC. (AGN) Rating Reiterated by Wells Fargo & Company
Allergan PLC. (NYSE:AGN)‘s stock had its “outperform” rating reiterated by equities researchers at Wells Fargo & Company in a note issued to investors on Monday.
A number of other research analysts also recently weighed in on the company. Royal Bank Of Canada reaffirmed a “buy” rating and set a $285.00 price target on shares of Allergan PLC. in a research note on Wednesday, September 6th. Cantor Fitzgerald reissued a “hold” rating on shares of Allergan PLC. in a report on Tuesday, August 29th. Cowen and Company reissued an “outperform” rating and set a $400.00 price objective on shares of Allergan PLC. in a report on Tuesday, August 29th. BidaskClub lowered Allergan PLC. from a “sell” rating to a “strong sell” rating in a report on Friday, August 25th. Finally, Argus reissued a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $275.49.
Allergan PLC. (NYSE AGN) traded up 0.113% during trading on Monday, reaching $233.815. 1,339,609 shares of the company’s stock were exchanged. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The company has a market capitalization of $78.17 billion, a price-to-earnings ratio of 7.124 and a beta of 1.18. The stock’s 50-day moving average price is $235.17 and its 200-day moving average price is $237.15.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the prior year, the business earned $3.35 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities analysts expect that Allergan PLC. will post $16.27 earnings per share for the current year.
Several hedge funds have recently modified their holdings of the stock. Intl Fcstone Inc. purchased a new stake in shares of Allergan PLC. in the second quarter worth $1,626,000. Phocas Financial Corp. purchased a new stake in shares of Allergan PLC. in the second quarter worth $150,000. Sentry Investment Management LLC raised its position in shares of Allergan PLC. by 1.0% in the second quarter. Sentry Investment Management LLC now owns 26,889 shares of the company’s stock worth $6,536,000 after buying an additional 265 shares in the last quarter. WFG Advisors LP raised its position in shares of Allergan PLC. by 20.9% in the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after buying an additional 137 shares in the last quarter. Finally, Toronto Dominion Bank raised its position in shares of Allergan PLC. by 25.2% in the second quarter. Toronto Dominion Bank now owns 113,770 shares of the company’s stock worth $27,651,000 after buying an additional 22,873 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.